Mark Bronstrup
Overview
Explore the profile of Mark Bronstrup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
2040
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gadiya Y, Genilloud O, Bilitewski U, Bronstrup M, von Berlin L, Attwood M, et al.
J Chem Inf Model
. 2025 Feb;
65(5):2416-2431.
PMID: 39987507
While the useful armory of antibiotic drugs is continually depleted due to the emergence of drug-resistant pathogens, the development of novel therapeutics has also slowed down. In the era of...
2.
Molinari G, Ribeiro S, Muller K, Mayer B, Rohde M, Arce-Rodriguez A, et al.
Microb Biotechnol
. 2025 Feb;
18(2):e70096.
PMID: 39937155
The DnaK (Hsp70) protein is an essential ATP-dependent chaperone foldase and holdase found in most organisms. In this study, combining multiple experimental approaches we determined FliC as major interaction partner...
3.
Heimann D, Kohnhauser D, Kohnhauser A, Bronstrup M
Drugs
. 2025 Jan;
85(3):293-323.
PMID: 39847315
The rise of antimicrobial resistance represents a significant global health threat, driven by the diminishing efficacy of existing antibiotics, a lack of novel antibacterials entering the market, and an over-...
4.
Risch T, Kolling D, Mostert D, Seedorf T, Heimann D, Kohnhauser D, et al.
NPJ Antimicrob Resist
. 2025 Jan;
2(1):33.
PMID: 39843645
Antimicrobial resistance is one of the major health threats of the modern world. Thus, new structural classes of antimicrobial compounds are needed in order to overcome existing resistance. Cystobactamids represent...
5.
Akula R, El Kilani H, Metzen A, Roske J, Zhang K, Gohl M, et al.
J Med Chem
. 2025 Jan;
68(3):2920-2941.
PMID: 39817813
The main protease M is a clinically validated target to treat infections by the coronavirus SARS-CoV-2. Among the first reported M inhibitors was the peptidomimetic α-ketoamide , whose cocrystal structure...
6.
Almasi E, Eisenhard L, Osbelt L, Lesker T, Vetter A, Knischewski N, et al.
Nat Commun
. 2025 Jan;
16(1):551.
PMID: 39789003
Competition among bacteria for carbohydrates is pivotal for colonization resistance (CR). However, the impact of Western-style diets on CR remains unclear. Here we show how the competition between Klebsiella oxytoca...
7.
Ramming I, Lang C, Hauf S, Kruger M, Worbs S, Peukert C, et al.
ACS Infect Dis
. 2024 Nov;
10(12):4103-4114.
PMID: 39576816
Shiga-toxin-producing (STEC) are important human pathogens causing diarrhea, hemorrhagic colitis, and severe hemolytic uremic syndrome. Timely detection of the multifaceted STEC is of high importance but is challenging and labor-intensive....
8.
Stappert M, Kohnhauser D, Seedorf T, Coetzee J, Rox K, Fuchs H, et al.
Commun Chem
. 2024 Nov;
7(1):252.
PMID: 39501041
Novel scaffolds for broad-spectrum antibiotics are rare and in strong demand because of the increase in antimicrobial resistance. The cystobactamids, discovered from myxobacterial sources, have a unique hexapeptidic scaffold with...
9.
Weber B, Ritchie N, Hilker S, Chan D, Peukert C, Deisinger J, et al.
ACS Infect Dis
. 2024 Oct;
10(11):3821-3841.
PMID: 39438291
To cause infection, bacterial pathogens must overcome host immune factors and barriers to nutrient acquisition. Reproducing these aspects of host physiology in vitro has shown great promise for antibacterial drug...
10.
Kohnhauser D, Seedorf T, Cirnski K, Heimann D, Coetzee J, Sordello S, et al.
J Med Chem
. 2024 Sep;
67(19):17162-17190.
PMID: 39303218
Cystobactamids have a unique oligoarylamide structure and exhibit broad-spectrum activity against Gram-negative and Gram-positive bacteria. In this study, the central α-amino acid of the cystobactamid scaffold was modified to address...